Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Recruiting 5Active not recruiting 4Withdrawn 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Thoracic 1NET 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 15Carcinoma, Hepatocellular 13Urinary Bladder Neoplasms 11Colorectal Neoplasms 11Small Cell Lung Carcinoma 9Neoplasms 8Carcinoma, Transitional Cell 8Stomach Neoplasms 7Neoplasm Metastasis 7Breast Neoplasms 6Triple Negative Breast Neoplasms 5Melanoma 5Prostatic Neoplasms 4Glioblastoma 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Carcinoma, Neuroendocrine 3Urethral Neoplasms 2Ureteral Neoplasms 2Turcot syndrome 2Solid Tumors 2Rectal Neoplasms 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Mesothelioma, Malignant 2Lymphoma, Follicular 2Glioma 2

Interventions

enzalutamide 33Abiraterone Acetate 28apalutamide 25Radiotherapy 25Prednisone 25Magnetic Resonance Spectroscopy 25Androgen Antagonists 24Leuprolide 21Radiosurgery 19darolutamide 18Docetaxel 17acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Gonadotropin-Releasing Hormone 14gallium 68 PSMA-11 12Specimen Handling 12Goserelin 12pembrolizumab 11Radiotherapy, Intensity-Modulated 11Radiation 11bicalutamide 10abiraterone 10Pluvicto 10Carboplatin 9Brachytherapy 92-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 9relugolix 8luprolide acetate gel depot 8Standard of Care 8Nivolumab 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms × atezolizumab × Clear all
NCT04262154 2026-05-11

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
28 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT04471727 2026-02-24

MK-6070-001

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2 Active not recruiting
232 enrolled
EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04751929 2026-02-20

Abemaciclib With or Without Atezolizumab for mCRPC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

Exelixis

Phase 3 Active not recruiting
575 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡